Treatment progress of relapsed and refractory Hodgkin lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 24-27, 2018.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-691601
Responsible library:
WPRO
ABSTRACT
Hodgkin lymphoma (HL) is a highly curable malignancy for most patients, while the treatment of relapsed and refractory HL is still a difficult and important field. A high dose of chemotherapy with autologous stem cell transplantation is treated as the preferred treatment with a high relapse incidence. The 59th American Society of Hematology Annual Meeting reported the recent progress of the treatment of relapsed and refractory HL, including the improvement of traditional high dose chemotherapy regimens, the new drugs or therapies like brentuximab vedotin, nivolumab, pembrolizumab and ibrutinib, and chimeric antigen receptor T-cell. This review focuses on these advances.
Full text:
Available
Database:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Leukemia & Lymphoma
Year:
2018
Document type:
Article